CASE IN POINT Understanding in a Veteran With a History of Combat and Multiple Sclerosis Angela Lee, AB; and Kalpana I. Nathan, MD A patient with significant combat history and previous diagnoses of multiple sclerosis and unspecified spectrum and other psychotic disorder was admitted with acute psychosis inconsistent with expected clinical presentations.

Angela Lee is a Medical ultiple sclerosis (MS) is an immune- present with distinct magnetic resonance imag- Student, and Kalpana mediated neurodegenerative disease ing (MRI) findings, such as diffuse periventric- Nathan is a Clinical 8 Associate Professor Mthat affects > 700,000 people in the ular lesions. Still, no conclusive criteria have (Affiliated) in the US.1 The hallmarks of MS pathology are axonal been developed to distinguish MS presenting Department of Psychiatry or neuronal loss, demyelination, and astrocytic as psychosis from a primary psychiatric illness, and Behavioral Sciences, both at Stanford gliosis. Of these, axonal or neuronal loss is the such as schizophrenia. University School of main underlying mechanism of permanent clini- In patients with combat history, it is possi- Medicine in California. cal disability. ble that both neurodegenerative and psychotic Kalpana Nathan also is MS also has been associated with an in- symptoms can be explained by autoantibody an Attending in the Veterans Affairs creased prevalence of psychiatric illnesses, formation in response to toxin exposure. When Palo Alto Health Care with mood disorders affecting up to 40% to soldiers were deployed to Iraq and Afghanistan, System in California. 60% of the population, and psychosis being they may have been exposed to multiple tox-

Correspondence: 2 The link Angela Lee reported in 2% to 4% of patients. icities, including depleted uranium, dust and 9 ([email protected]) between MS and mood disorders, including fumes, and numerous infectious diseases. Gulf and depression, was docu- War illness (GWI) or chronic multisymptom illness mented as early as 1926, with mood disorders (CMI) encompass a cluster of symptoms, such hypothesized to be manifestations of central as chronic pain, chronic fatigue, irritable bowel nervous system (CNS) inflammation.3 More re- , dermatitis, and seizures, as well as cently, inflammation-driven microglia have been mental health issues such as depression and hypothesized to impair hippocampal connec- anxiety experienced following exposure to these tivity and activate glucocorticoid-insensitive in- combat environments.10,11 flammatory cells that then overstimulate the In light of this diagnostic uncertainty, the au- hypothalamic-pituitary-adrenal axis.4,5 thors detail a case of a patient with significant Although the prevalence of psychosis in combat history previously diagnosed with MS patients with MS is significantly rarer, averag- and unspecified schizophrenia spectrum and ing between 2% and 4%.6 A Canadian study other psychotic disorder (USS & OPD) presenting by Patten and colleagues reviewed data from with acute psychosis. 2.45 million residents of Alberta and found that those who identified as having MS had a 2% CASE PRESENTATION to 3% prevalence of psychosis compared with A 35-year-old male veteran, with a history of 0.5% to 1% in the general population.7 The MS, USS & OPD, posttraumatic stress disor- connection between psychosis and MS, sim- der, and traumatic brain injuries (TBIs) was ad- ilar to that between mood disorders and MS, mitted to the psychiatric unit after being found has been described as a common regional by the police lying in the middle of a busy inter- demyelination process. Supporting this, MS section, internally preoccupied. On admission, manifesting as psychosis has been found to he reported a week of auditory hallucinations

S32 • FEDERAL PRACTITIONER SPECIAL ISSUE • JUNE 2019 from birds with whom he had been communi- at age 18 years to serve in the Marine Corps cating telepathically, and a recurrent visual hallu- (2001-2006). His service included deployment cination of a tall man in white and purple robes. to Afghanistan, where he received a purple He had discontinued his medica- heart. Upon his return, he received BA and MS tion, aripiprazole 10 mg, a few weeks prior for degrees. He married and had 2 daughters but unknown reasons. He was brought to the hos- became estranged from his wife. By his most pital by ambulance, where he presented with recent admission, he was unemployed and living disorganized thinking, tangential pro- with his half-sister. cess, and active auditory and visual hallucina- On the first day of this most recent psychi- tions. The differential diagnoses included USS & atric hospitalization, he was restarted on aripip- OPD, schizophrenia, schizoaffective disorder and razole 10 mg daily, and a medicine consult was ruled out substance-induced psychotic disorder, sought to evaluate the progression of his MS. No and psychosis as a manifestation of MS. new onset neurologic symptoms were noted, but The patient had 2 psychotic episodes prior he had possible residual lower extremity hyper- to this presentation. He was hospitalized for his reflexia and tandem gait incoordination. The ep- first psychotic break in 2015 at age 32, when he isodes of psychotic and neurologic symptoms had tailed another car “to come back to reality” appeared independent, given that his psychiatric and ended up in a motor vehicle accident. Dur- history preceded the onset of his MS. ing that admission, he reported weeks of thought The patient reported no visual hallucinations broadcasting, conspiratorial delusions, and rac- starting day 2, and he no longer endorsed audi- ing . Two years later, he was admitted tory hallucinations by day 3. However, he con- to a psychiatric intensive care unit for his second tinued to appear internally preoccupied and was episode of severe psychosis. After several trials noticed to be pacing around the unit. On day 4 of different antipsychotic medications, his most he presented with newly pressured speech and recent pharmacologic regimen was aripiprazole flights of ideas, while his affect remained euthy- 10 mg once daily. mic and his sleep stayed consistent. In combi- His medical history was complicated by nation with his ongoing pacing, his newfound 2 TBIs, in November 2014 and January 2015, symptoms were hypothesized to be possibly with normal computed tomography (CT) scans. akathisia, an adverse effect (AE) of aripiprazole. He was diagnosed with MS in December 2017, As such, on day 5 his dose was lowered to 5 mg when he presented with intractable emesis, left daily. He continued to report no hallucinations facial numbness, right upper extremity ataxia, and demonstrated progressively increased emo- nystagmus, and imbalance. An MRI scan re- tional range. A MRI scan was done on day 6 in vealed multifocal bilateral hypodensities in his case a new lesion could be identified, suggesting periventricular, subcortical, and brain stem a primary MS flare-up; however, the scan identi- white matter. Multiple areas of hyperintensity fied no enhancing lesions, indicating no ongoing were visualized, including in the right periatrial demyelination. After a neurology consult corrob- region and left brachium pontis. More than orated this conclusion, he was discharged in sta- 5 oligoclonal bands on lumbar puncture con- ble condition on day 7. firmed the diagnosis. As is the case with the majority of patients He was treated with IV methylprednisolone with MS-induced psychosis, he continued to followed by a 2-week prednisone taper. Within have relapsing psychiatric disease even after MS 1 week, he returned to the psychiatric unit with treatment had been started. Unfortunately, be- worsening symptoms and received a second cause this patient had stopped taking his atypi- dose of IV steroids and plasma exchange treat- cal antipsychotic medication several weeks prior ment. In the following months, he completed a to his hospitalization, we cannot clarify whether course of rituximab infusions and physical ther- his psychosis stems from a primary psychiatric apy for his dysarthria, gait abnormality, and vi- vs MS process. sion impairment. His social history was notable for multi- DISCUSSION ple first-degree relatives with schizophrenia. He Presently, treatment preferences for MS- reported a history of sexual and verbal abuse related psychosis are divided between atypi- and attempted suicide once at age 13 years by cal and glucocorticoids. Some hanging himself with a bathrobe. He left home suggest that the treatment remains similar

JUNE 2019 • FEDERAL PRACTITIONER SPECIAL ISSUE • S33 Psychosis in Patient with MS

between MS-related psychosis and primary of MRI imaging done at his initial psychotic epi- psychotic disorders in that atypical antipsy- sodes cannot exclude a primary MS diagnosis. chotics are the standard of care.12 A variety of Still, his lack of MRI findings at his most recent atypical antipsychotics have been used suc- hospitalization, negative symptomatology, and cessfully in case reports, including zipradisone, strong history of schizophrenia make a primary risperidone, olanzapine, quetiapine, and ar- psychotic disorder likely. ipiprazole.13,14 First-generation antipsychotics Following his future clinical course will be and other psychotropic drugs that can pre- necessary to determine the etiology of his psy- cipitate extra-pyramidal AEs are not recom- chotic episodes. Future episodes of psycho- mended given their potential additive effect sis with neurologic symptoms would suggest to motor deficits associated with MS.12 Alter- a primary MS diagnosis and potential benefit natively, several case reports have found that of immunosuppressant treatment, whereas re- MS-related psychotic symptoms respond to peated psychotic breaks with minimal tempo- glucocorticoids more effectively, while caution- ral lobe involvement or demyelination as seen on ing that glucocorticoids can precipitate psy- MRI would be suspicious for separate MS and chosis and depression.15,16 One review article psychotic disease processes. Further research found that 90% of patients who received cor- on treatment regimens for patients experienc- ticosteroids saw an improvement in their psy- ing psychosis as a manifestation of MS is still chotic symptoms.2 necessary. Finally, it is possible that our patient’s neu- ropsychiatric symptoms can be explained by Author disclosures The authors report no actual or potential conflicts of interest autoantibody formation in response to toxin with regard to this article. exposure during his time in Afghanistan. In a pilot study of veterans with GWI, Abou- Disclaimer Donia and colleagues found 2-to-9 fold in- The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline crease in autoantibody reactivity levels of the Medical Communications Inc., the US Government, or any following neuronal and glial-specific proteins of its agencies. This article may discuss unlabeled or inves- relative to healthy controls: neurofilament trip- tigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combina- let proteins, tubulin, microtubule-associated tions—including indications, contraindications, warnings, and tau proteins, microtubule-associated protein-2, adverse effects—before administering pharmacologic therapy to patients. myelin basic protein, myelin-associated glyco- protein, glial fibrillary acidic protein, and cal- References 17,18 cium-calmodulin kinase II. Many of these 1. Wallin MT, Culpepper WJ, Campbell JD, et al. The autoantibodies are longstanding explicit mark- prevalence of MS in the : A population- based estimate using health claims data. Neurology. ers for neurodegenerative disorders, given that 2019;92(10):e1029-e1040. they target proteins and antigens that support 2. Camara-Lemarroy CR, Ibarra-Yruegas BE, Rodriguez- axonal transport and myelination. Still Gulf War Gutierrez R, Berrios-Morales I, Ionete C, Riskind P. The varieties of psychosis in multiple sclerosis: a systematic veteran status has yet to be explicitly linked to review of cases. Mult Scler Relat Disord. 2017;12:9-14. an increased risk of MS,19 making this hypoth- 3. Cottrel SS, Wilson SA. The affective symptomatology of disseminated sclerosis: a study of 100 cases. J Neurol esis less likely for our patient. Future research Psychopathology. 1926;7(25):1-30. should address the clinical and therapeutic im- 4. Johansson V, Lundholm C, Hillert J, et al. Multiple scle- plications of different autoantibody levels in rosis and psychiatric disorders: comorbidity and sib- ling risk in a nationwide Swedish cohort. Mult Scler. combat veterans with psychosis. 2014;20(14):1881-1891. 5. Rossi S, Studer V, Motta C, et al. Neuroinflammation drives anxiety and depression in relapsing-remitting multiple scle- CONCLUSION rosis. Neurology. 2017;89(13):1338-1347. For patients with MS, and psy- 6. Gilberthorpe TG, O’Connell KE, Carolan A, et al. The spec- chotic symptoms should warrant a MRI given trum of psychosis in multiple sclerosis: a clinical case se- ries. Neuropsychiatric disease and treatment. 2017;13:303. the possibility of a psychiatric manifestation of 7. Patten SB, Svenson LW, Metz LM. Psychotic disorders in MS relapse. Ultimately, our patient’s presenta- MS: population-based evidence of an association. Neurol- tion was inconsistent with the expected clinical ogy 2005;65(7):1123-1125. 8. Kosmidis MH, Giannakou M, Messinis L, Papathanaso- presentations of both a primary psychotic dis- poulos P. Psychotic features associated with multiple scle- order and psychosis as a manifestation of MS. rosis. Int Rev Psychiatry. 2010; 22(1):55-66. 9. US Department of Veterans Affairs. Public health: military His late age at his first psychotic break is atypi- exposures. https://www.publichealth.va.gov/exposures/. cal for primary psychotic disease, and the lack Updated April 16, 2019. Accessed May 13, 2019.

S34 • FEDERAL PRACTITIONER SPECIAL ISSUE • JUNE 2019 Psychosis in Patient with MS

10. DeBeer BB, Davidson D, Meyer EC, Kimbrel NA, Gulliver 15. Enderami A, Fouladi R, Hosseini HS. First-episode psy- SB, Morissette SB. The association between toxic ex- chosis as the initial presentation of multiple sclerosis: a posures and chronic multisymptom illness in veterans of case report. Int Medical Case Rep J. 2018;11:73-76. the wars of Iraq and Afghanistan. J Occup Environ Med. 16. Fragoso YD, Frota ER, Lopes JS, et al. Severe depression, 2017;59(1):54-60. suicide attempts, and ideation during the use of interferon 11. Kang HK, Li B, Mahan CM, Eisen SA, Engel CC. Health beta by patients with multiple sclerosis. Clin Neuropharma- of US veterans of 1991 Gulf War: a follow-up survey in 10 col. 2010;33(6):312-316. years. J Occup Environ Med. 2009;51(4):401-410. 17. Abou-Donia MB, Conboy LA, Kokkotou E, et al. Screening 12. Murphy R, O’Donoghue S, Counihan T, et al. Neuropsychi- for novel central nervous system biomarkers in veterans atric of multiple sclerosis. J Neurol Neurosurg with Gulf War Illness. Neurotoxicol Teratol. 2017;61:36-46. Psychiatry. 2017;88(8):697-708. 18. Abou-Donia MB, Lieberman A, Curtis L. Neural autoan- 13. Davids E, Hartwig U, Gastpar, M. Antipsychotic treat- tibodies in patients with neurological symptoms and his- ment of psychosis associated with multiple scle- tories of chemical/mold exposures. Toxicol Ind Health. rosis. Prog Neuro Psychopharmacol Biol Psychiatry. 2018;34(1):44-53. 2004;28(4):743-744. 19. Wallin MT, Kurtzke JF, Culpepper WJ, et al. Multiple scle- 14. Lo Fermo S, Barone R, Patti F, et al. Outcome of psychiat- rosis in Gulf War era veterans. 2. Military deployment and ric symptoms presenting at onset of multiple sclerosis: a risk of multiple sclerosis in the first Gulf War. Neuroepide- retrospective study. Mult Scler. 2010;16(6):742-748. miology. 2014;42(4):226-234.

JUNE 2019 • FEDERAL PRACTITIONER SPECIAL ISSUE • S35